C92.31
C92.31 — Myeloid sarcoma, in remission
Billable / specific codeICD-10-CM
C92.31 is a billable, specific ICD-10-CM code for myeloid sarcoma, in remission. It is valid for submission on a claim.
Risk adjustment
C92.31 risk-adjusts. Under the CMS-HCC V28 model it maps to this category:
- HCC 17 Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic4.209 RAF
Coefficient shown for the Community Non-dual Aged segment. A higher HCC in the same hierarchy will suppress this one, so capturing it does not always add score.
Medicare coverage
C92.31 is named in 32 Medicare coverage policies — 30 listing it as supporting medical necessity, and 2 listing it as NOT covered. Which of them applies to you depends on your Medicare contractor, and coverage genuinely differs by state.
- A56462Billing and Coding: Erythropoiesis Stimulating Agents (ESA)not covered
- A60435Billing and Coding: Erythropoiesis Stimulating Agents (ESA)not covered
- A52479Oral Anticancer Drugs - Policy Article
- A52479Oral Anticancer Drugs - Policy Article
Related codes at this level
Codes that share C92.3. If C92.31 is not quite right, the correct code is usually one of these.
Questions about C92.31
- Is C92.31 a billable ICD-10-CM code?
- Yes. C92.31 is a billable, specific ICD-10-CM code and is valid for submission on a claim.
- Where does C92.31 sit in the tabular list?
- Neoplasms (C00-D49), in the block Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96).